



**American Professional Agency**

LEADERS IN MEDICAL PROFESSIONAL LIABILITY INSURANCE

# Are You Protected Against Cyber-Attacks?

## Liability Insurance for Psychiatrists

**Ask about a  
Cyber  
Endorsement**

**Scan for a Quote**



**AmericanProfessional.com**

Endorsed By

AMERICAN  
PSYCHIATRIC  
ASSOCIATION





## Asst/Assoc/Prof of Clinical Pediatrics/ Physician Surgeon/Psychiatry

(Search extended through 8/21/2024)

**Hiring Department:** Pediatrics

**Location:** Peoria, IL USA

**Requisition ID:** 1020638

**Posting Close Date:** 8/21/2024

The University of Illinois College of Medicine at Peoria (UICOMP) seeks physicians for positions at the level of Professor, Associate Professor or Assistant Professor to enhance an important clinical program.

Pediatric Psychiatrist positions require candidates who are BC in Psychiatry and have completed 4 years in residency and 2 years in fellowship training in Pediatric Psychiatry. Candidates with scholarly and research interests are highly desirable, along with experience in teaching medical students and residents.

### Position Summary

The Department of Pediatrics, University of Illinois College of Medicine at Peoria is seeking psychiatrist who has completed a fellowship in Child and Adolescent Psychiatry at the level of Assistant/Associate Professor or Professor.

### Duties & Responsibilities

Responsibilities – Child Psychiatrist

- Participate in undergraduate, graduate and continuing education programs of the Department.
- Provide outpatient diagnostic and management services for patients in the region with general psychiatric and behavioral needs.
- Provide inpatient psychiatric consultation for children and adolescents.
- Organize and conduct research programs in Child Psychiatry.
- Perform other duties of a university faculty member including committee assignments, curriculum development, student counseling, and administration.

### Minimum Qualifications

- Eligible for licensure in Illinois
- Board Certified in Psychiatry
- Board Certified/Board Eligible in Child and Adolescent Psychiatry

### About University of Illinois College of Medicine, Peoria (UICOMP) Department of Pediatrics and OSF Healthcare Children's Hospital of Illinois:

UICOMP is one of the three regional campuses of the University of Illinois College of Medicine, one of the largest public medical schools in the country. UICOMP's educational programs include 244 medical students and 300 residents/fellows in 21 different post graduate programs. The Department of Pediatrics is one of the largest departments at UICOMP. In collaboration with the OSF HealthCare Children's Hospital of Illinois, the Department has 19 divisions and over 145 faculty members providing general pediatrics and subspecialty services to the pediatric population in Central Illinois.

### About Children's Hospital of Illinois

The current research infrastructure within the Department includes office of research, a dedicated biostatistician and internal research funding mechanism to support our faculty. The primary teaching hospital of UICOMP is Children's Hospital of Illinois, a tertiary care facility serving a 37-county region with a population base of over two million. Children's Hospital of Illinois provides comprehensive services to children, including Level IV NICU and a state-designated Pediatric Critical Care Center. Children's Hospital of Illinois is a major medical facility with 136 beds and a 32-bed critical care unit and the only Level 1 trauma center in Illinois outside of Chicago. There are existing resources through UICOMP and Children's Hospital of Illinois for seeding research funding, quality and outcomes focused academic work and innovation in health education.

### About Peoria, IL

One of the oldest communities in Illinois with a population of 112,936, Peoria is equal distance from Chicago and St. Louis. Here we have an enviable standard of living, exciting venues within a 15-20 minute drive from our homes, safe streets, quality and quantity shopping, our own symphony, our own ballet, Broadway Theater League, museums, art guilds, first-class medical facilities, the nation's oldest community theater and oldest Santa Claus parade.

Our vibrant riverfront showcases a multitude of festivals and celebrations that light up the summer nights much like our extraordinary Fourth of July Sky Concert fireworks show that draws well over 100,000 annually. Citizens are flocking to live in the refurbished warehouses and lofts on Water Street that produce the perfect lifestyle for a 24/7 city.

We have many global businesses that allow Peoria to play all over the world through their products and services. Peoria has begun to diversify its economy with infotech industries as well. Thus our business community attracts some of the brightest graduates throughout the nation.

For fullest consideration, please submit your application by 6/19/2024 at:  
<https://uic.com/ux/ats/careersite/1/home/requisition/6600?c=uic>

The University of Illinois System is an equal opportunity employer, including but not limited to disability and/or veteran status, and complies with all applicable state and federal employment mandates. Please visit Required Employment Notices and Posters at <https://www.hr.uillinois.edu/cms/one.aspx?portalId=4292&pageId=5705> to view our non-discrimination statement and find additional information about required background checks, sexual harassment/misconduct disclosures, and employment eligibility review through E-Verify.

The University of Illinois conducts background checks on all job candidates upon acceptance of a contingent offer of employment. Background checks will be performed in compliance with the Fair Credit Reporting Act.

As an EOE/AA employer, the University of Illinois encourages applications from individuals regardless of an applicant's race, color, religion, sex, gender identity, sexual orientation, national origin, and Veteran or disability status.

The university provides accommodations to applicants and employees. Request an Accommodation at <https://jobs.uic.edu/request-and-accommodation/> Accommodation at <https://jobs.uic.edu/request-and-accommodation/>


## NEW TITLES FROM AMERICAN PSYCHIATRIC ASSOCIATION PUBLISHING

### The American Psychiatric Association Publishing Textbook of Geriatric Psychiatry, Sixth Edition

Edited by David C. Steffens, M.D., M.H.S., and  
Kristina F. Zdanys, M.D.

2023 • 848 pages • ISBN 978-1-61537-340-6 • Hardcover  
\$200.00 • Item #37340

2023 • 848 pages • ISBN 978-1-61537-437-3 • eBook  
\$160.00 • Item #37437



### Textbook of Hospital Psychiatry, Second Edition

Edited by Harsh K. Trivedi, M.D., M.B.A., and  
Steven S. Sharfstein, M.D., M.P.A.

2023 • 703 pages • ISBN 978-1-61537-345-1 • Hardcover  
\$155.00 • Item #37345

2023 • 703 pages • ISBN 978-1-61537-440-3 • eBook  
\$124.00 • Item #37440




### The American Psychiatric Association Publishing Textbook of Mood Disorders, Second Edition

Edited by Charles B. Nemeroff, M.D., Ph.D.,  
Alan F. Schatzberg, M.D., Natalie Rasgon, M.D., Ph.D., and  
Stephen M. Strakowski, M.D.

2022 • 986 pages • ISBN 978-1-61537-331-4 • Hardcover  
\$195.00 • Item #37331

2022 • 986 pages • ISBN 978-1-61537-452-6 • eBook  
\$156.00 • Item #37452




### Textbook of Psychiatric Administration and Leadership, Third Edition

Edited by Sy Saeed, M.D., M.S., FACP, John Lauriello, M.D.,  
and Laura Weiss Roberts, M.D., M.A.

2023 • 544 pages • ISBN 978-1-61537-337-6 • Hardcover  
\$154.00 • Item #37337

2023 • 544 pages • ISBN 978-1-61537-434-2 • eBook  
\$123.00 • Item #37434



### Gabbard's Textbook of Psychotherapeutic Treatments, Second Edition

Edited by Holly Crisp, M.D., and Glen O. Gabbard, M.D.

2023 • 830 pages • ISBN 978-1-61537-326-0 • Hardcover  
\$145.00 • Item #37326

2023 • 830 pages • ISBN 978-1-61537-406-9 • eBook  
\$116.00 • Item #37406




### Textbook of Antisocial Personality Disorder

Edited by Donald W. Black, M.D., and Nathan J. Kolla, M.D.

2022 • 535 pages • ISBN 978-1-61537-323-9 • Hardcover  
\$105.00 • Item #37323

2022 • 535 pages • ISBN 978-1-61537-322-2 • eBook  
\$84.00 • Item #37322



AMERICAN  
PSYCHIATRIC  
ASSOCIATION  
PUBLISHING



ORDER @ [www.appi.org](http://www.appi.org)  
Email: [appi@psych.org](mailto:appi@psych.org)  
Toll Free: 1-800-368-5777

20% Discount for American Psychiatric  
Association Members

25% Discount for APA Resident-Fellow Members

AH2318B

# Ongoing **ADHD** symptoms causing her to slip?

Stop the Slide.  
**Start Qelbree.**

**Novel nonstimulant  
treatment that works<sup>1,2</sup>**

**Qelbree**<sup>®</sup> ONCE-DAILY  
**viloxazine**  
extended-release capsules  
100 mg 150 mg 200 mg  
**Rethink ADHD Symptom Control**



Patient portrayal.

## INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

## IMPORTANT SAFETY INFORMATION

### WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

**In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.**

## CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

## WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
- *Activation of mania or hypomania*: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
- *Somnolence and fatigue*: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

## ADVERSE REACTIONS

The most common adverse reactions ( $\geq 5\%$  and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

## PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting [www.womensmentalhealth.org/preg](http://www.womensmentalhealth.org/preg).

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.

REFERENCES: 1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. 2. Food and Drug Administration. Novel drug approvals for 2021. May 13, 2022. Accessed January 7, 2023. <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>.

**Please see the brief summary of full Prescribing Information including Boxed Warning, on adjacent pages, or visit [QelbreeHCP.com](http://QelbreeHCP.com).**



Qelbree and Rethink ADHD Symptom Control are registered trademarks of Supernus Pharmaceuticals, Inc.  
©2024 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2024-0013



**Qelbree<sup>®</sup> (viloxazine extended-release capsules), for oral use**  
**BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION**

For full prescribing information, see package insert.

**WARNING: SUICIDAL THOUGHTS AND BEHAVIORS**

**In clinical studies, higher rates of suicidal thoughts and behavior were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.**

**INDICATIONS AND USAGE**

Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

**CONTRAINDICATIONS**

Qelbree is contraindicated in patients receiving concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, because of an increased risk of hypertensive crisis.

Qelbree should not be taken when receiving concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range.

**WARNINGS AND PRECAUTIONS**

**Suicidal Thoughts and Behaviors**

Higher rates of suicidal thoughts and behaviors were reported in pediatric and adult patients with ADHD treated with Qelbree than in patients treated with placebo.

Among 1019 patients exposed to Qelbree 100 mg to 400 mg in short-term trials, a total of nine patients (0.9%) reported suicidal ideation (N=6), behavior (N=1) or both (N=2). Eight patients reported suicidal ideation or behavior on the Columbia Suicide Severity Rating Scale (C-SSRS), a validated scale that assesses suicide risk. An additional patient treated with Qelbree reported suicidal behavior during the clinical trials, but did not report it on the C-SSRS. Among 463 patients treated with placebo in these studies, two patients (0.4%) reported suicidal ideation on the C-SSRS. No patients treated with placebo reported suicidal behavior. No completed suicides occurred in these trials.

Among 189 adults treated with Qelbree, a total of three patients (1.6%) reported suicidal ideation on the C-SSRS, versus 0 of 183 adults treated with placebo. No adults treated with either Qelbree or placebo reported suicidal behavior on the C-SSRS in the study. No attempted or completed suicides occurred in the trial.

Patients treated with Qelbree had higher rates of insomnia and irritability. Although a causal link between the emergence of insomnia and irritability and the emergence of suicidal impulses has not been established, there is a concern that these and other symptoms such as depressed mood, anxiety, agitation, akathisia, mania, hypomania, panic attacks, impulsive behavior, and aggression may represent precursors to emerging suicidal ideation or behavior. Thus, patients being treated with Qelbree should be observed for the emergence of precursor symptoms.

Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes.

Consider changing the therapeutic regimen, including possibly discontinuing Qelbree, in patients who are experiencing emergent suicidal thoughts and behaviors or symptoms that might be precursors to emerging suicidal ideation or behavior, especially if these symptoms are severe or abrupt in onset, or were not part of the patient's presenting symptoms. Advise family members or caregivers of patients to monitor for the emergence of suicidal ideation or behavior, and to report such symptoms immediately to the healthcare provider.

**Effects on Blood Pressure and Heart Rate**

Qelbree can cause an increase in heart rate and diastolic blood pressure.

In a clinical study in patients 6 to 11 years of age, 34/154 (22%) of patients treated with Qelbree 100 mg daily had a  $\geq 20$  beat per minute (bpm) increase in heart rate at any time point in the clinical trial, compared to 15/159 (9%) of patients who received placebo. This finding was observed in 84/268 (31%) who received the 200 mg dose, compared to 39/262 (15%) of patients in the placebo group, and in 28/100 (28%) of patients who received the 400 mg dose, compared to 24/103 (23%) of patients who received placebo.

In a clinical study in patients 12 to 17 years of age, 22/99 (22%) of patients treated with Qelbree 200 mg daily had a  $\geq 20$  bpm increase in heart rate at any time point in the clinical trial, compared to 15/104 (14%) of patients who received placebo. This finding was observed in 69/205 (34%) who received the 400 mg dose, compared to 35/201 (17%) of patients in the placebo group.

In patients ages 12 to 17 years, 52/205 (25%) of patients treated with Qelbree 400 mg daily had a  $\geq 15$  mmHg increase in diastolic blood pressure at any time in the clinical trial, compared to 26/201 (13%) of patients in the placebo group.

In a clinical study in adult patients (18 to 60 years of age), 52/178 (29%) of patients treated daily with Qelbree (200 mg to 600 mg) had a  $\geq 20$  beat per minute (bpm) increase in heart rate at any time point in the clinical trial, compared to 23/181 (13%) of patients who received placebo. Of patients treated daily with Qelbree (200 to 600 mg), 23/178 (13%) had a  $\geq 15$  mmHg increase in diastolic blood

pressure at any time in the clinical trial, compared to 16/181 (9%) of patients in the placebo group.

Assess heart rate and blood pressure prior to initiating treatment with Qelbree, following increases in dosage, and periodically while on therapy.

**Activation of Mania or Hypomania**

Noradrenergic drugs, such as Qelbree, may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression.

**Somnolence and Fatigue**

Qelbree can cause somnolence and fatigue. In the short-term, placebo-controlled clinical trials in pediatric patients 6 to 17 years of age with ADHD, somnolence (including lethargy and sedation) was reported in 16% of Qelbree-treated patients compared to 4% of placebo-treated patients. Fatigue was reported in 6% of Qelbree-treated patients compared to 2% of placebo-treated patients.

In adults, somnolence was reported in 6% of Qelbree-treated patients versus 2% in placebo-treated patients. Fatigue was reported in 12% of Qelbree-treated patients versus 3% of placebo-treated patients.

Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by Qelbree.

**ADVERSE REACTIONS**

**Clinical Trials Experience**

The safety of Qelbree has been evaluated in 1118 patients 6 to 17 years of age with ADHD exposed to one or more doses in short-term (6 to 8 week), randomized, double-blind, placebo-controlled trials.

A total of 682 pediatric patients were treated for at least 6 months, and 347 pediatric patients for at least 12 months with Qelbree.

The safety of Qelbree has been evaluated in 189 adult patients (18 to 60 years of age) with ADHD exposed to one or more doses in a short-term (6 week), randomized, double-blind, placebo-controlled trial. A total of 277 adult patients with ADHD have been exposed to one or more doses of Qelbree.

Eighty-four adult patients were treated for at least 6 months, and 22 adult patients for at least 12 months.

The data described below reflect exposure to Qelbree in 826 patients (6 to 17 years) who participated in randomized, double-blind, placebo-controlled trials with doses ranging from 100 mg to 400 mg. The population (N=826) was 65% male, 35% female, 54% White, 41% Black, 4% multiracial, and 1% other races.

**Adverse Reactions Leading to Discontinuation of Qelbree Treatment:** Approximately 3% (n=27) of the 826 patients receiving Qelbree in clinical studies discontinued treatment due to an adverse reaction. The adverse reactions most commonly associated with discontinuation of Qelbree were somnolence (n=5), nausea (n=3), headache (n=2), irritability (n=2), tachycardia (n=2), fatigue (n=2), and decreased appetite (n=2).

**Most Common Adverse Reactions (occurring at  $\geq 5\%$  and at least twice the placebo rate for any dose):** somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability.

Tables 1 and 2 below lists adverse reactions that occurred in at least 2% of patients treated with Qelbree and more frequently in Qelbree-treated patients than in placebo-treated patients. Table 1 data represents pooled data from pediatric patients 6-17 years of age who were enrolled in randomized, placebo-controlled trials of Qelbree. Table 2 represents data from adults with ADHD who were enrolled in a flexible-dose, randomized, placebo-controlled trial of Qelbree at doses of 200mg to 600mg.

**Table 1. Adverse Reactions Reported in  $\geq 2\%$  of Pediatric Patients (6 to 17 Years of Age) Treated with Qelbree and at a Rate of Greater than Placebo-Treated Patients in Placebo-Controlled ADHD Studies**

Body System Adverse Reaction	Placebo N=463 (%)	Qelbree			
		100mg N=154 (%)	200mg N=367 (%)	400mg N=305 (%)	All Qelbree N=836 (%)
<b>Nervous system disorders</b>					
Somnolence*	4	12	16	19	16
Headache*	7	10	11	11	11
<b>Metabolic and nutritional disorders</b>					
Decreased appetite	0.4	5	8	8	7
<b>Infections and infestations</b>					
Upper respiratory tract infections*	6	5	7	8	7
<b>Body as a Whole - General disorders</b>					
Fatigue	2	4	5	9	6
Pyrexia	0.2	3	2	1	2
<b>Gastrointestinal system disorders</b>					
Abdominal Pain*	4	3	6	7	5
Nausea	3	1	4	7	5
Vomiting	2	5	3	6	4



**Table 1. Adverse Reactions Reported in ≥2% of Pediatric Patients (6 to 17 Years of Age) Treated with Qelbree and at a Rate Greater than Placebo-Treated Patients in Placebo-Controlled ADHD Studies (continued)**

Body System Adverse Reaction	Placebo N=463 (%)	Qelbree			
		100mg N=154 (%)	200mg N=367 (%)	400mg N=305 (%)	All Qelbree N=836 (%)
<b>Psychiatric disorders</b>					
Insomnia*	1	2	5	5	4
Irritability	1	3	2	5	3

\*The following items were combined:

**Somnolence:** somnolence, lethargy, sedation

**Headache:** headache, migraine, migraine with aura, tension headache

**Upper respiratory tract infection:** nasopharyngitis, pharyngitis, sinusitis, upper respiratory tract infection, viral sinusitis, viral upper respiratory tract infection

**Abdominal pain:** abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper

**Insomnia:** initial insomnia, insomnia, middle insomnia, poor quality sleep, sleep disorder, terminal insomnia

The data described below reflect exposure to Qelbree in 189 adults with ADHD who participated in the flexible-dose, randomized, double-blind, placebo-controlled trial with doses ranging from 200 mg to 600 mg. The population (N=189) was 56% male, 44% female, 81% White, 12% Black, 3% Asian, 3% other races and 1% multiracial.

**Adverse Reactions Leading to Discontinuation of Qelbree Treatment:**

Approximately 9% of the 189 patients receiving Qelbree in clinical studies discontinued treatment due to an adverse reaction. The adverse reactions most commonly associated with discontinuation of Qelbree were fatigue (n=4), insomnia (n=3), constipation (n=3), and headache (n=2).

**Most Common Adverse Reactions (occurring at ≥5% and at least twice the placebo rate of Qelbree):** insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

Listed here are adverse reactions that occurred in at least 2% of patients treated with Qelbree and more frequently in the Qelbree-treated patients than in the placebo-treated patients. Table 2 represents data from adults with ADHD who were enrolled in a flexible-dose, randomized, placebo-controlled trial of Qelbree at doses of 200 mg to 600 mg.

**Table 2. Adverse Reactions Reported in ≥2% of Adults Treated with Qelbree and at a Rate Greater than Placebo-Treated Patients in a Flexible-Dose Placebo-Controlled ADHD Study**

Body System Adverse Reaction	Placebo N=183 (%)	Qelbree (200 mg to 600 mg) N=189 (%)
<b>Psychiatric disorders</b>		
Insomnia*	7	23
Irritability	3	4
<b>Nervous system disorders</b>		
Headache*	7	17
Somnolence*	2	6
Dizziness	2	4
<b>Gastrointestinal system disorders</b>		
Nausea	3	12
Dry mouth	2	10
Constipation	1	6
Vomiting	1	4
Gastroesophageal reflux disease	1	2
<b>Body as a Whole - General disorders</b>		
Fatigue	3	12
<b>Metabolic and nutritional disorders</b>		
Decreased appetite	3	10
<b>Cardiac disorders</b>		
Tachycardia	1	4

\*The following items were combined:

**Somnolence:** somnolence, lethargy, sedation

**Headache:** headache, migraine, migraine with aura, tension headache

**Insomnia:** initial insomnia, insomnia, middle insomnia, poor quality sleep, sleep disorder, terminal insomnia

## DRUG INTERACTIONS

### Drugs Having Clinically Important Interactions with Qelbree

#### Monoamine Oxidase Inhibitors (MAOI)

- Clinical Impact: Concomitant use of Qelbree with an MAOI may lead to a potentially life-threatening hypertensive crisis.
- Intervention: Concomitant use of Qelbree with an MAOI or within 2 weeks after discontinuing an MAOI is contraindicated.

#### Sensitive CYP1A2 Substrates or CYP1A2 Substrates with a Narrow Therapeutic Range

- Clinical Impact: Viloxazine is a strong CYP1A2 inhibitor. Concomitant use of viloxazine significantly increases the total exposure, but not peak exposure, of

sensitive CYP1A2 substrates, which may increase the risk of adverse reactions associated with these CYP1A2 substrates.

- Intervention: Coadministration with Qelbree is contraindicated.

#### Moderate Sensitive CYP1A2 Substrate

- Clinical Impact: Viloxazine is a strong CYP1A2 inhibitor. Concomitant use of viloxazine significantly increases the total, but not peak, exposure of sensitive CYP1A2 substrates, which may increase the risk of adverse reactions associated with these CYP1A2 substrates.

- Intervention: Not recommended for coadministration with Qelbree. Dose reduction may be warranted if coadministered.

#### CYP2D6 Substrates

- Clinical Impact: Viloxazine is a weak inhibitor of CYP2D6, and increases the exposure of CYP2D6 substrates when coadministered.

- Intervention: Monitor patients for adverse reactions and adjust dosages of CYP2D6 substrates, as clinically indicated.

#### CYP3A4 Substrates

- Clinical Impact: Viloxazine is a weak inhibitor of CYP3A4 which increases the exposure of CYP3A4 substrates when coadministered.

- Intervention: Monitor patients for adverse reactions and adjust dosages of CYP3A4 substrates, as clinically indicated.

## USE IN SPECIFIC POPULATIONS

### Pregnancy

#### Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388, or visiting online at [www.womensmentalhealth.org/peg](http://www.womensmentalhealth.org/peg).

#### Risk Summary

Based on findings from animal reproduction studies, viloxazine may cause maternal harm when used during pregnancy. Discontinue Qelbree when pregnancy is recognized unless the benefits of therapy outweigh the potential risk to the mother. Available data from case series with viloxazine use in pregnant women are insufficient to determine a drug-associated risk of major birth defects, miscarriage or adverse maternal outcomes.

In animal reproduction studies, oral administration of viloxazine during the period of organogenesis caused fetal toxicities and delayed fetal development in the rat and maternal toxicities in the rabbit at doses approximately equal to the maximum recommended human dose (MRHD) of 600mg in adults, based on mg/m<sup>2</sup>. Oral administration of viloxazine to pregnant rats and mice during pregnancy and lactation caused maternal toxicities and deaths and fetal toxicities at doses equal to or less than the MRHD of 600mg in adults, based on mg/m<sup>2</sup>, respectively.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcome. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

#### Lactation

##### Risk Summary

There are no data on the presence of viloxazine in human milk, the effects on the breastfed infant, or the effects on milk production. Viloxazine is likely present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Qelbree and any potential adverse effects on the breastfed child from Qelbree or from the underlying maternal condition.

#### Geriatric Use

Clinical trials of Qelbree in the treatment of ADHD did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients.

#### Renal Impairment

Dosage reduction is recommended in patients with severe (eGFR of < 30 mL/min/1.73m<sup>2</sup> [MDRD]) renal impairment.

No dosage adjustment of Qelbree is recommended in patients with mild to moderate (eGFR of 30 to 89 mL/min/1.73m<sup>2</sup> [MDRD]) renal impairment.

The exposure of viloxazine increases in patients with renal impairment.

## OVERDOSAGE

### Human Experience

The pre-market clinical trials with Qelbree do not provide information regarding symptoms of overdose.

Literature reports from post marketing experience with immediate-release viloxazine include cases of overdosage from 1000 mg to 6500 mg (1.7 to 10.8 times the maximum recommended daily dose). The most reported symptom was drowsiness. Impaired consciousness, diminished reflexes, and increased heart rate have also been reported.

### Treatment and Management

There is no specific antidote for Qelbree overdose. Administer symptomatic and supportive treatment as appropriate. In case of overdose, consult a Certified Poison Control Center (1-800-222-1222 or [www.poisson.org](http://www.poisson.org)).

# THE AMERICAN PSYCHIATRIC ASSOCIATION

800 Maine Avenue, S.W., Suite 900, Washington, D.C. 20024

(888) 357-7924 (toll-free inside the U.S. and Canada)

web site: [www.psychiatry.org](http://www.psychiatry.org) • e-mail: [apa@psych.org](mailto:apa@psych.org)

## Chairpersons of Committees, Councils, and Task Forces

### STANDING COMMITTEES

#### Bylaws

Edward R. Herman, J.D., M.D.

#### Elections

Glenn A. Martin, M.D.

#### Ethics

Philip J. Candilis, M.D.

#### Finance and Budget

Steven S. Sharfstein, M.D.

*Audit:* Steve Koh, M.D., M.P.H., M.B.A.

*Investment Oversight:* David Fassler, M.D.

#### Joint Reference

Theresa M. Miskimen, M.D.

#### Membership

Tanuja Gandhi, M.D.

#### Nominating

Petros Levounis, M.D., M.A.

#### Tellers

Katherine M. Napalinga, M.D.

### NON-STANDING COMMITTEES

#### Conflict of Interest

Gabrielle L. Shapiro, M.D.

#### Structural Racism Accountability

Kamalika Roy, M.D., M.C.R.

### COUNCILS

#### Council on Addiction Psychiatry

Lief Fenno, M.D., Ph.D.

#### Council on Advocacy and Government Relations

Lannis L. Tynes, M.D.

*Advocacy and Litigation Funding:* Patrick Aquino, M.D.

#### Council on Children, Adolescents, and Their Families

Lisa Fortuna, M.D., M.P.H., M.Div.

#### Council on Communications

Howard Liu, M.D., M.B.A.

#### Council on Consultation-Liaison Psychiatry

Philip A. Bialer, M.D.

#### Council on Geriatric Psychiatry

Badr Ratnakaran, M.D.

#### Council on Healthcare Systems and Financing

Robert L. Trestman, M.D., Ph.D.

*Integrated Care:* Shannon M. Kinnan, M.D.

*RRVS, Codes and Reimbursement:* Sarah Parsons, D.O.

*Reimbursement for Psychiatric Care:* Sander Koyfman, M.D.

#### Council on International Psychiatry and Global Health

Pamela Collins, M.D., M.P.H.

#### Council on Medical Education and Lifelong Learning

Rashi Aggarwal, M.D.

*Innovation:* Manu Sharma, M.D.

*Scientific Program:* Michael F. Myers, M.D.

*Scientific Program—Mental Health Services Conference (Oct. to Oct. tenure):* Lawrence Malak, M.D.

*Vestermark Award Committee:* Josepha A. Cheong, M.D.

*Well-Being and Burnout:* Lorenzo Norris, M.D.

#### Council on Minority Mental Health and Health Disparities

Walter Wilson, Jr., M.D.

#### Council on Psychiatry and Law

Richard Martinez, M.D., M.H.

*Judicial Action:* Reena Kapoor, M.D.

#### Council on Quality Care

Glenda Wrenn-Gordon, M.D., M.S.H.P.

*Mental Health Information Technology:* Darlene R. King, M.D.

*Quality and Performance Measurement:* David S. Kroll, M.D.

*Practice Guidelines:* Daniel J. Anzia, M.D.

*Telepsychiatry:* Shabana Khan, M.D.

#### Council on Research

Jonathan E. Alpert, M.D., Ph.D.

*Climate Change and Mental Health:* Joshua Wortzel, M.D.


*Psychiatric Dimensions of Disasters:* James C. West, M.D.

#### Council on Women's Mental Health

Ludmila B. De Faria, M.D.



# DSM-5-TR<sup>®</sup> DIAGNOSTIC CRITERIA APP



The new DSM-5-TR<sup>®</sup> Diagnostic Criteria Mobile App has been fully redesigned and is a concise companion to the ultimate psychiatric reference, *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR<sup>®</sup>)*. It includes the fully revised diagnostic classification, as well as all the diagnostic criteria from DSM-5-TR<sup>®</sup> in an easy-to-use format. This handy reference provides mental health practitioners, researchers, and students quick access to the information essential to making a diagnosis.

## Features:

- Fully redesigned and updated user interface
- Improved presentation of tables and charts
- Dual-use modes for toggling between the diagnostic criteria and classification
- Up-to-date access to ICD-10-CM codes for clinical and administrative use
- Over 70 modified criteria sets with helpful clarifications since publication of DSM-5<sup>®</sup>
- Bookmark frequently used information and add notes for easy reference later.

Available for both **iOS** and **Android** compatible devices through the iTunes App store and Google Play.



# Go Online

Visit [ajp.psychiatryonline.org](http://ajp.psychiatryonline.org) for these features!

## AJP in Advance

*Discover the latest research advances before they appear in print*

### **Testing Quantitative and Qualitative Sex Effects in a National Swedish Twin-Sibling Study of Posttraumatic Stress Disorder**

The largest study to date to examine the influences of genetics and environment, both shared and unique, on PTSD and to test for sex differences in genetic risk found that PTSD was moderately heritable, with a significant sex difference in that the degree of heritability was higher among women.

### **National Trends in Emergency Department Visits for Suicide Attempts and Intentional Self-Harm**

A study that estimated national annual trends and characteristics of emergency department visits for suicide attempts and intentional self-harm in the United States found a significant national increase in both from 2011 to 2020.

## AJP Audio and Video

Lina Jonsson, Ph.D., joins **AJP Audio** to discuss "Association of Occupational Dysfunction and Hospital Admissions With Different Polygenic Profiles in Bipolar Disorder," p. 620.

In an issue highlights video, AJP Deputy Editor Daniel S. Pine discusses "Pharmacogenomic Clinical Support Tools for the Treatment of Depression" (Baum et al., p. 591) and "A Nationwide Target Trial Emulation Assessing the Risk of Antidepressant-Induced Mania Among Patients With Bipolar Depression" (Rohde et al., p. 630).

## AJP CME

You can earn CME credits by reading articles in *The American Journal of Psychiatry*. Three articles in this issue form a short course that consists of reading the article and answering three multiple-choice questions with a single correct answer for up to 1 AMA PRA Category 1 Credit™ each. Credit is issued only to subscribers of the online AJP CME Course Program.

See the list below for articles in this month's issue that are the subject of a CME quiz.

### **In this issue**

---

Pharmacogenomic Clinical Support Tools for the Treatment of Depression (Baum et al., p. 591)

---

Association of Occupational Dysfunction and Hospital Admissions With Different Polygenic Profiles in Bipolar Disorder (Jonsson et al., p. 620)

---

Association of Lower Rostral Anterior Cingulate GABA+ and Dysregulated Cortisol Stress Response With Altered Functional Connectivity in Young Adults With Lifetime Depression: A Multimodal Imaging Investigation of Trait and State Effects (Ironside et al., p. 639)

---

@APAPubJournals



Psychiatry Online



AMERICAN  
PSYCHIATRIC  
ASSOCIATION  
PUBLISHING



www.appi.org  
1-800-368-5777  
appi@psych.org